Valeo Foods Group Acquires Leading Italian Bakery Company Dal Colle
Valeo Foods Group (“Valeo Foods” or “The Group”), one of Europe’s leading producers of quality sweets, treats and snacks, has completed the process to acquire assets of a renowned Italian producer of high-quality bakery products, Dal Colle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529721501/en/
Ronald Kers, CEO of Valeo Foods Group (Photo: Business Wire)
With a history and heritage dating back 120 years, Dal Colle produces a range of bakery products, sweet treats and snacks for every occasion including Pandori, Panettoni and Croissants. Its range of over 180 products is currently sold in over 35 countries around the world.
Dal Colle provides a highly complementary addition to Valeo’s expanding Italian platform and operations, built on its initial acquisition of Balconi in 2015 and the subsequent acquisitions of Val D’Enza in 2017 and IDP Pattini in 2023.
Ronald Kers, CEO of Valeo Foods Group, said: "Dal Colle is a fantastic addition to the Valeo Foods portfolio which already boasts many of Europe’s finest and most established brands, with deep heritage and connections with consumers. On a commercial level it diversifies and strengthens our product offering and completes our range of quality confectionary and sweet treats in this market, ranging from iconic sponge cakes to wafers and biscuits. It also adds considerable new manufacturing and logistical capabilities to our Italian platform, which will support our growth ambitions in Italy and across Europe. This is very consistent with our vision to position Valeo Foods as the undisputed European sweet treats champion.”
Alberto Alfieri, CEO of Valeo Foods Italy & President of Balconi Spa, said: “We have long admired Dal Colle who share our passion for delivering high-quality products to consumers and their heritage range and operational footprint are highly complementary to Valeo Foods Italy and the Balconi business. We very much look forward to welcoming close to 90 new colleagues to our team and work with them to accelerate the growth of our enlarged Italian business.”
Valeo Foods Group is one of Europe’s fastest growing food groups and one of Europe’s leading producers and purveyors of quality sweets, treats and snacks.
With revenues in excess of €1.5 billion, the Valeo Foods portfolio includes over 80 brands enjoyed by customers in over 106 countries around the world including Balconi, Carstens, Jacobs, Barrat, Fox’s Mints, Taveners, Poppets, Rowse Honey and Maple Crest. The Group employs over 4,500 people across 30 manufacturing facilities and offices in the UK, Italy, Germany, the Netherlands, Ireland, the Czech Republic and Canada. Valeo Foods Group is owned by leading global investment firm Bain Capital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529721501/en/
Contact information
Media Enquiries on behalf of Valeo Foods Group:
Robert Brown, Associate Partner, Reputation Inc
rbrown@reputation-inc.com
+353 85 725 2626
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 06:25:00 EET | Press release
FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,
Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 05:31:00 EET | Press release
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig
OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 04:00:00 EET | Press release
Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl
Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 23:30:00 EET | Press release
The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
